Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TEMPLE CITY, Calif., Oct. 25, 2016 -- Fulgent Genetics, Inc. (Nasdaq:FLGT) (“Fulgent Genetics” or the “company”) today announced that Ming Hsieh, its Chairman and Chief Executive Officer, Dr. Harry Gao, its Chief Science Officer, and Paul Kim, its Chief Financial Officer, are scheduled to present at the 25th Annual Credit Suisse Healthcare Conference at the Phoenician hotel in Scottsdale, Arizona on Monday, November 7, 2016 at 4:00 PM MST (3:00 PM PST).
The live audio webcast and accompanying slide presentation can be accessed in the Investor Relations section of the company’s website, www.fulgentgenetics.com, and an audio replay of the webcast will remain available on the company’s website through December 7, 2016.
About Fulgent Genetics, Inc.
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy, and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 200 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Contacts The Blueshirt Group Bob Jones, 212-871-5570, [email protected] Chris Danne, 415-217-5865, [email protected]
